Prognostic parameters and detection of cardiac amyloidosis with hybrid 18F-Florbetaben-PET/MRI: an exploratory observational study
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07733-x ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Lukas Kessler und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany. lukas.kessler@uk-essen.de. Hauptthemen laut MEDLINE: Aniline Compounds, Stilbenes, Positron-Emission Tomography, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Essen.
Abstract (Originalsprache)
Purpose
Positron emission tomography (PET) with amyloid-binding tracers was shown to have high sensitivity for the detection of both transthyretin (ATTR) and light-chain (AL) cardiac amyloidosis (CA). Recent studies describe prognostic value of imaging biomarkers from bone scintigraphy and 18 F-Florbetapir. The aim of this study was to evaluate the value of imaging biomarkers from 18 F-Florbetaben PET, cardiac magnetic resonance (CMR), and echocardiography imaging for prediction of major adverse cardiac events (MACE) in comparison to serum biomarkers in patients with different types of CA.
Methods
Patients who underwent cardiac 18 F-Florbetaben PET/MRI were prospectively enrolled and received clinical follow-up for up to 36 months and MACE were reported (NCT07154381). Scans were reported by two blinded, nuclear medicine physicians. Imaging biomarkers including average retention index (RI), T1 mapping/ extracellular volume (ECV) and serological markers were estimated and their association with MACE free survival was analyzed.
Results
Twenty-one patients with confirmed CA were enrolled. MACEs were reported in 14 of 21 patients (66.7%). Higher average RI was the only imaging biomarker that was a significant predictor for MACE in uni- and multivariate analysis (HR = 4.02, 95%CI: 1.25-12.9, p < 0.05). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was a significant predictor in uni- but not in multivariate analysis. Patients with AL-CA showed a higher rate of MACE than patients with other subtypes.
Conclusion
Integrated 18 F-Florbetaben PET/MR allows diagnosis, subtype differentiation and outcome predication of CA. The average RI was the only significant and independent prognostic imaging biomarker of MACE. Future prospective studies are warranted to investigate benefits for patient management and risk assessment in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany. lukas.kessler@uk-essen.de.
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany. lukas.kessler@uk-essen.de.
- West German Amyloidosis Center, Hufelandstrasse 55, 45147, Essen, Germany. lukas.kessler@uk-essen.de.
- Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 , Essen, Germany.
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
- West German Amyloidosis Center, Hufelandstrasse 55, 45147, Essen, Germany.
ORCID-Profile: Lukas Kessler
Förderung
- Universitätsklinikum Essen
Zitieren
APA
Kessler, L., Tonscheidt, W., Nassenstein, K., Settelmeier, S., Carpinteiro, A., Reinhardt, H. C., Hagenacker, T., Umutlu, L., Kleinschnitz, C., Wernhart, S., Michel, L., Chodyla, M. K., Schaarschmidt, B. M., Schlosser, T. W., Fendler, W. P., Barbato, F., Papathanasiou, M., Rischpler, C., Herrmann, K., …, & Kersting, D. (2026). Prognostic parameters and detection of cardiac amyloidosis with hybrid 18F-Florbetaben-PET/MRI: an exploratory observational study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07733-x
Vancouver
Kessler L, Tonscheidt W, Nassenstein K, Settelmeier S, Carpinteiro A, Reinhardt HC, et al. Prognostic parameters and detection of cardiac amyloidosis with hybrid 18F-Florbetaben-PET/MRI: an exploratory observational study. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07733-x
BibTeX
@article{Kessler2026,
author = {Kessler, Lukas and Tonscheidt, Wibke and Nassenstein, Kai and Settelmeier, Stephan and Carpinteiro, Alexander and Reinhardt, H Christian and Hagenacker, Tim and Umutlu, Lale and Kleinschnitz, Christoph and Wernhart, Simon and Michel, Lars and Chodyla, Michal K and Schaarschmidt, Benedikt M and Schlosser, Thomas-Wilfried and Fendler, Wolfgang P and Barbato, Francesco and Papathanasiou, Maria and Rischpler, Christoph and Herrmann, Ken and Rassaf, Tienush and Kersting, David},
title = {Prognostic parameters and detection of cardiac amyloidosis with hybrid 18F-Florbetaben-PET/MRI: an exploratory observational study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07733-x}
}
EUVIMED